The main market opportunities for breast cancer antibody drug conjugates (ADCs) lie in addressing unmet needs in HER2-positive and HER2-low tumors, leveraging precision targeting and reducing systemic ...

Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration ...

Xcellon Biologics will incorporate IntoCell’s OHPAS drug-linker system into its range of ADC development suites.

New research has uncovered a built-in resistance mechanism to antibody–drug conjugates in some breast cancers and identified ...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug ...

NetTargets employs an AI system that combines multi-omics data with neural network modelling for drug discovery.

Ajinomoto Co., Inc. has signed a licensing agreement with Astellas Pharma Inc. for the use of AJICAP—an antibody-drug conjugate (ADC) development and manufacturing technology—as part of its CDMO ...

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global ...

We're really looking at some of these progress and the platform. So before we go that and we really talk about the current development in the toxin-based antibody drug conjugate, ADCs. As we know, ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...